Supplementary Table S1. Univariate and Multivariate Logistic Regression Models of In-Hospital Outcomes														
	In-hospital death				ARDS				ICU admission					
Variables	**OR (95% CI)**	**p value**	**adj. OR (95% CI)**	**p value**	**OR (95% CI)**	**p value**	**adj. OR (95% CI)**	**p value**	**OR (95% CI)**	**p value**	**adj. OR (95% CI) – 1st model**	**p value**	**adj. OR (95% CI) -2nd model**	**p value**
Male sex	1.180 (0.68-2.045)	0.556	2.223 (0.887-5.572)	0.088	1.393 (0.852-2.280)	0.187	2.194 (1.031-4.669)	0.041	2.222 (1.218-4.054)	0.009	2.278 (1.022-5.075)	0.044	2.575 (1.163-5.701)	0.020
Age (years)	1.069 (1.038-1.100)	<0.001	1.042 (0.998-1.087)	0.064	1.015 (0.995-1.036)	0.143	1.043 (1.006-1.081)	0.021	0.985 (0.963-1.008)	0.193	1.046 (1.005-1.089)	0.026	1.050 (1.008-1.093)	0.018
BMI (kg/m^2)	0.892 (0.829-0.96)	0.002	0.892 (0.797-0.999)	0.048	0.983 (0.936-1.032)	0.491	1.007 (0.937-1.081)	0.853	1.021 (0.970-1.075)	0.421	1.038 (0.966-1.116)	0.311	1.048 (0.976-1.125)	0.194
HbA1c (%)	1.180 (0.963-1.444)	0.110	1.146 (0.843-1.558)	0.384	1.117 (0.925-1.349)	0.249	1.085 (0.845-1.393)	0.524	1.149 (0.943-1.400)	0.168	1.074 (0.826-1.397)	0.592	1.204 (0.921-1.573)	0.175
Antidiabetic tablets	0.662 (0.315-1.394)	0.278			1.490 (0.69-3.216)	0.310			1.195 (0.508-2813)	0.684				
Years living with Diabetes (years)	1.02 (0.984-1.057)	0.282			0.975 (0.941-1.010)	0.153	0.941 (0.890-0.995)	0.033	0.943 (0.9-0.987)	0.012	0.918 (0.858-0.982)	0.013	0.935 (0.876-0.998)	0.045
Metformin	0.632 (0.354-1.128)	0.120			1.027 (0.625-1.688)	0.916			1.387 (0.785-2.452)	0.260				
Sulfonylureas	1.155 (0.478-2.788)	0.749			1.084 (0.487-2.414)	0.843			1.067 (0.421-2.701)	0.891				
DPP4	1.846 (1.063-3.205)	0.03	2.639 (1.148-6.068)	0.022	1.945 (1.189-3.183)	0.008	2.507 (1.278-4.916)	0.007	1.819 (1.032-3.207)	0.039	2.524 (1.217-5.232)	0.013		
GLP1-RA	0.479 (0.163-1.403)	0.179			0.68 (0.288-1.607)	0.380			0.766 (0.286-2.057)	0.598				
Insulin	1.059 (0.547-2.051)	0.865			0.679 (0.357-1.289)	0.237			0.561 (0.253-1.244)	0.155			0.259 (0.074-0.909)	0.035
Insulin+GLP1RA	0.794 (0.171-3.676)	0.768			0.845 (0.23-3.102)	0.799			0.385 (0.049-3)	0.362				
SGLT2i	0.536 (0.218-1.317)	0.174			0.937 (0.467-1.881)	0.937			0.781 (0.333-1.831)	0.569				
ACEi/ ARBs	0.84 (0.481-1.466)	0.539			0.697 (0.427-1.139)	0.150	1.018 (0.411-2.521)	0.970	0.537 (0.302-0.954)	0.034	0.951 (0.350-2.578)	0.921	0.699 (0.259-1.888)	0.480
Statins	0.828 (0.476-1.441)	0.505			0.877 (0.537-1.433)	0.600			0.760 (0.430-1.342)	0.344				
IHD	2.417 (1.342-4.353)	0.003	1.902 (0.731-4.954)	0.118	1.550 (0.892-2.692)	0.120	1.218 (0.571-2.596)	0.610	1.085 (0.56-2.101)	0.809				
CVA	5.058 (2.235-11.443)	<0.001	5.357 (1.308-21.943)	0.02	1.583 (0.687-3.649)	0.281	4.319 (1.124-16.604)	0.033	0.383 (0.088-1.663)	0.200	1.170 (0.191-7.166)	0.865	1.440 (0.245-8.462)	0.687
Revascularization of any artery	1.291 (0.498-3.345)	0.599			1.212 (0.516-2.846)	0.659			1.082 (0.395-2.965)	0.879				
Hypertension	1.069 (0.57-2.004)	0.835			0.653 (0.386-1.107)	0.114	0.592 (0.226-1.552)	0.286	0.448 (0.249-0.808)	0.008	0.407 (0.147-1.129)	0.063	0.489 (0.179-1.340)	0.164
CHF	2.161 (1.094-4.270)	0.027	1.552 (0.485-4.968)	0.459	1.074 (0.542-2.127)	0.838			0.514 (0.195-1.357)	0.179	0.282 (0.072-1.105)	0.069	0.340 (0.087-1.328)	0.121
Malignancy	2.780 (1.165-6.631)	0.021	1.093 (0.248-4.822)	0.907	2.103 (0.916-4.831)	0.080	1.379 (0.366-5.195)	0.635	1.241 (0.448-3.439)	0.678				
ESRD	3.345 (1.761-6.353)	<0.001	2.226 (0.867-5.718)	0.096	1.483 (0.789-2.789)	0.221	0.925 (0.364-2.350)	0.870	0.837 (0.373-1.879)	0.666				
Immunosuppresion	1.843 (0.685-4.959)	0.226			1.261 (0.473-3.359)	0.643			0.522 (0.118-2.308)	0.392				

Liver disease	0.733 (0.087-6.205)	0.776			1.274 (0.243-6.692)	0.775			2.111 (0.399-11.163)	0.379				
COPD	1.309 (0.59-2.906)	0.508			1.476 (0.73-2.984)	0.279	1.416 (0.571-3.508)	0.453	1.219 (0.533-2.789)	0.639				
Chronic cognitive deficit	2.616 (1.056-6.484)	0.038	4.163 (1.064-16.288)	0.040	1.131 (0.431-2.969)	0.802			0.226 (0.03-1.709)	0.150	0.141 (0.014-1.416)	0.096	0.172 (0.018-1.619)	0.124

OR; odds ratio, adj OR; adjusted odds ratio, BMI; Body mass index, DPP4i; Dipeptidyl peptidase 4 inhibitors, GLP1-RA; Glucagon-like peptide-1 receptor agonists, SGTL2i; Sodium-glucose cotransporter-2 inhibitors, ACEi; Angiotensin-converting enzyme inhibitors, ARBs; Angiotensin II receptor blockers, IHD; Ischemic Heart disease, CVA; cerebrovascular accident, CHF; congestive heart failure, ESRD; end stage renal disease, COPD; chronic obstructive pulmonary disease

Supplementary Table S2. Cox proportional regression model for 28-day mortality

	p value	adj. HRs	95,0% CI	
			Lower	Upper
Male gender	0,012	2,468	1,222	4,984
BMI (kg/m²)	0,250	0,960	0,895	1,029
Age (years)	0,003	1,058	1,019	1,099
Ischemic Heart Disease	0,070	1,893	0,949	3,774
Cerebrovascular accident	0,050	2,379	0,999	5,663
End-stage kidney disease	0,160	1,688	0,813	3,507
DPP4 inhibitors	0,027	2,014	1,082	3,750
Congestive Heart Failure	0,839	0,917	0,397	2,118
Malignancy	0,919	1,049	0,419	2,626
Chronic neurologic deficit	0,001	4,262	1,759	10,322
Years since T2D diagnosis	0,021	0,948	0,905	0,992

Adj. HRs; adjusted hazard ratios, BMI; Body mass index, DPP4i; Dipeptidyl peptidase 4 (DPP4), T2D; Type 2 Diabetes